| Lymphocyte Count and High Fluorescent Count (HFLC) Correlate With Liver Disorder in Dengue Fever Patients (NCT05407181) | Nurhasan Agung Prabowo | 2022-06-03 |
| Study of AT-752 in Patients With Dengue Infection (NCT05466240) | Atea Pharmaceuticals, Inc. | 2022-04-29 |
| Baromètre Santé Adulte 2021-2022 (NCT05218304) | Agence Sanitaire et Sociale de Nouvelle Calédonie | 2021-07-26 |
| Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) in Participants Aged ≥9 to <15 Years (NCT04313244) | Takeda | 2021-05-15 |
| Prospective Study on the Risks of Dengue Fever for the Fetus. (NCT04822441) | Centre Hospitalier Universitaire de la Réunion | 2021-03-19 |
| Sylvatic Transmission of Zika, Dengue, and Chikungunya Viruses in Thailand and Cambodia (NCT04434846) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-02-08 |
| Mobile Point of Care Diagnostic Testing for Ebola Virus Disease in DRC (NCT04235361) | University of Stirling | 2021-01-15 |
| A Cluster-randomized Trial to EValuate the Efficacy of Wolbachia-InfecTed Aedes Aegypti Mosquitoes in Reducing the Incidence of Arboviral Infection in Brazil (EVITA Dengue) (NCT04514107) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-09-09 |
| New Tools for Predicting Capillary Leak Shock During Dengue Fever (NCT04422782) | Centre Hospitalier de Cayenne | 2020-05-14 |
| Surveillance of Suspected Dengue Cases for Access to Care for Subjects Identified as Seronegative or Undetermined Before Receiving CYD Dengue Vaccine in Previous Clinical Studies in Colombia (NCT04113330) | Sanofi Pasteur, a Sanofi Company | 2020-01-31 |
| Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose (NCT03999996) | Takeda | 2019-11-12 |
| Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults (NCT02741128) | Sanofi Pasteur, a Sanofi Company | 2019-11-06 |
| IC14 in Adult Patients With Dengue Fever (NCT03875560) | Implicit Bioscience | 2019-05-01 |
| Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of Shelf Life in Healthy Adults (NCT03771963) | Takeda | 2019-03-28 |
| Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults (NCT03746015) | Takeda | 2018-12-28 |
| Celgosivir or Modipafant as Treatment for Adult Participants With Uncomplicated Dengue Fever in Singapore (NCT02569827) | Singapore General Hospital | 2018-12-01 |
| Investigating Vector-Borne Determinants of Aedes Transmitted Arboviral Infections in Cambodia: An Observational Longitudinal Cohort Study in Children (NCT03534245) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-07-01 |
| Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue (NCT03423173) | Takeda | 2018-02-12 |
| Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects (NCT02992418) | Sanofi Pasteur, a Sanofi Company | 2016-12-19 |
| Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue Vaccine (NCT02948933) | Sanofi Pasteur, a Sanofi Company | 2016-12-14 |
| Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® (NCT02993757) | Sanofi Pasteur, a Sanofi Company | 2016-12-01 |
| Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® (NCT02979535) | Sanofi Pasteur, a Sanofi Company | 2016-11-16 |
| Dengue Serostatus Study in the Philippines (NCT03465254) | University of the Philippines | 2016-11-01 |
| Detection of Dengue Virus in Plasma of Patients in Nepal (NCT03620487) | Karius, Inc. | 2016-10-26 |
| Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule (NCT02824198) | Sanofi Pasteur, a Sanofi Company | 2016-07-01 |
| Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age (NCT02628444) | Sanofi Pasteur, a Sanofi Company | 2016-05-02 |
| Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule (NCT02623725) | Sanofi Pasteur, a Sanofi Company | 2016-04-14 |
| Association of Host Genetics With Vaccine Efficacy and Study of Immune Correlates of Risk From a Tetravalent Dengue Vaccine (NCT02827162) | Sanofi Pasteur, a Sanofi Company | 2016-03-29 |
| The Clinical Epidemiology of Hospitalized Dengue Cases in Malaysia (NCT02510638) | Clinical Research Centre, Malaysia | 2015-09-01 |
| Safety and Immunogenicity With Two Different Serotype 2 Potencies of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Adults in Singapore (NCT02425098) | Takeda | 2015-06-03 |
| Ketotifen as a Treatment for Vascular Leakage During Dengue Fever (NCT02673840) | National University Hospital, Singapore | 2015-03-01 |
| Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants (NCT02302066) | Takeda | 2014-12-05 |
| Studies on the Pathogen, Vector Control and Clinical Treatment of Dengue Fever in Guangzhou (NCT02608047) | Guangzhou 8th People's Hospital | 2014-10-01 |
| Factors Associated With Poor Dengue Outcomes in Malaysia (NCT02510690) | Clinical Research Centre, Malaysia | 2014-10-01 |
| Efficacy and Safety of Ivermectin Against Dengue Infection (NCT02045069) | Mahidol University | 2014-02-01 |
| Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine (NCT01943825) | Sanofi Pasteur, a Sanofi Company | 2013-11-05 |
| Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study (NCT01983553) | Sanofi Pasteur, a Sanofi Company | 2013-09-10 |
| Impact of SC vs IM Administration of DENVax (TDV) on Safety and Immunogenicity (NCT01728792) | Takeda | 2013-01-22 |
| A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults (in Puerto Rico) (NCT01702857) | U.S. Army Medical Research and Development Command | 2012-11-01 |
| A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults (NCT01666652) | U.S. Army Medical Research and Development Command | 2012-09-01 |
| Celgosivir as a Treatment Against Dengue (NCT01619969) | Singapore General Hospital | 2012-07-01 |
| Clinical Specimens Testing Program of Dengue Antigen Detection Reagents (NCT01917422) | Kaohsiung Medical University Chung-Ho Memorial Hospital | 2012-07-01 |
| Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India (NCT01550289) | Sanofi Pasteur, a Sanofi Company | 2012-03-01 |
| Chinese and Western Medicine Treatment of Fever Associated With Bleeding Symptoms (NCT01973855) | Guangzhou 8th People's Hospital | 2012-01-01 |
| Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine (NCT01488890) | Sanofi Pasteur, a Sanofi Company | 2011-12-06 |
| Evaluation of the Safety and the Ability of a DNA Vaccine to Protect Against Dengue Disease (NCT01502358) | U.S. Army Medical Research and Development Command | 2011-12-01 |
| Safety Study of a Vaccine (DENV-1 PIV) to Prevent Dengue Disease (NCT01502735) | U.S. Army Medical Research and Development Command | 2011-12-01 |
| International Research Consortium on Dengue Risk Assessment, Management, and Surveillance (NCT01550016) | University of Heidelberg Medical Center | 2011-10-01 |
| Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children (NCT01477671) | Sanofi Pasteur, a Sanofi Company | 2011-09-01 |
| Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America (NCT01374516) | Sanofi Pasteur, a Sanofi Company | 2011-06-08 |
| Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia (NCT01373281) | Sanofi Pasteur, a Sanofi Company | 2011-06-03 |
| Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue Fever (NCT01224639) | Inviragen Inc. | 2010-10-11 |
| Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia (NCT01134263) | Sanofi Pasteur, a Sanofi Company | 2010-10-05 |
| Laboratory Diagnosis and Prognosis of Severe Dengue (NCT01421732) | Oxford University Clinical Research Unit, Vietnam | 2010-10-01 |
| Role of Andi-d in Dengue Fever: a Pilot Study (NCT01443247) | Post Graduate Institute of Medical Education and Research, Chandigarh | 2010-09-01 |
| Prospective Surveillance of Febrile Illness for Dengue-Endemic Areas in Asia (NCT01218906) | Sanofi | 2010-08-01 |
| Study of Febrile Illness for Dengue-Endemic Areas in Latin America (NCT01293331) | Sanofi | 2010-08-01 |
| A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines (NCT01064141) | Sanofi | 2010-01-01 |
| Adult Dengue Platelet Study (NCT01030211) | Tan Tock Seng Hospital | 2010-01-01 |
| Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America (NCT00993447) | Sanofi Pasteur, a Sanofi Company | 2009-10-01 |
| Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31-7164) in Healthy Adults (NCT00831012) | National Institute of Allergy and Infectious Diseases (NIAID) | 2009-09-01 |
| Diagnosis and Characterization of Dengue Fever in Children (NCT00946218) | St. Jude Children's Research Hospital | 2009-07-01 |
| Study of HBV-001 D1 in Healthy Adults (NCT00936429) | Hawaii Biotech, Inc. | 2009-07-01 |
| Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore (NCT00880893) | Sanofi Pasteur, a Sanofi Company | 2009-04-07 |
| Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects (NCT00875524) | Sanofi Pasteur, a Sanofi Company | 2009-03-01 |
| Efficacy and Safety of Dengue Vaccine in Healthy Children (NCT00842530) | Sanofi Pasteur, a Sanofi Company | 2009-02-01 |
| Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years (NCT00788151) | Sanofi Pasteur, a Sanofi Company | 2008-09-26 |
| Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults (NCT00740155) | Sanofi Pasteur, a Sanofi Company | 2008-08-01 |
| Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US (NCT00617344) | Sanofi | 2008-04-17 |
| Investigation of the Immuno-regulation and Viral Hepatitis Among Patients With or After Dengue Fever Infection (NCT00688389) | Kaohsiung Medical University Chung-Ho Memorial Hospital | 2007-07-01 |
| A Study of Two Doses of WRAIR Dengue Vaccine Administered Six Months Apart to Healthy Adults and Children (NCT00468858) | U.S. Army Medical Research and Development Command | 2007-07-01 |
| Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects (NCT00730288) | Sanofi | 2006-08-01 |
| Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-200,201) in Healthy Adults (NCT00270699) | National Institute of Allergy and Infectious Diseases (NIAID) | 2006-06-01 |
| Safety of and Immune Response to a Dengue Virus Vaccine (rDEN1delta30) in Healthy Adults (NCT00089908) | National Institute of Allergy and Infectious Diseases (NIAID) | 2004-09-01 |
| A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children (NCT00384670) | U.S. Army Medical Research and Development Command | 2003-08-01 |